TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update November 13, 2025
Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC November 10, 2025
Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares November 10, 2025
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 November 10, 2025
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results November 3, 2025
